Syndax Pharmaceuticals, Inc. Unamortized Loss Reacquired Debt, Noncurrent
Syndax Pharmaceuticals, Inc. (SNDX) had Unamortized Loss Reacquired Debt, Noncurrent of $49.00 thousand as of 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Balance Sheet › Assets › Regulated Entity, Other Assets, Noncurrent
us-gaap:UnamortizedLossReacquiredDebtNoncurrent · last filed 2020-05-07
- 2020-03-31: Unamortized Loss Reacquired Debt, Noncurrent $49.00K.
| Period end | Unamortized Loss Reacquired Debt, Noncurrent |
|---|---|
| 2020-03-31 | $49.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |